Abstract:
An apparatus and method for locking a gun. The apparatus includes a dummy round configured for insertion into a firing chamber of a gun, a locking component configured for coupling with the dummy round, and an elongated sleeve rotatably coupled with the locking component. The locking component includes a keyed head positioned within a longitudinal channel of the elongated sleeve. The locking component and elongated sleeve are insertable through the discharge end of a gun's barrel. An actuating mechanism, such as a key is insertable through the channel of the elongated sleeve to engage with the keyed head and rotate the locking mechanism relative to the elongated sleeve. Rotation of the locking mechanism effects a friction lock between the locking mechanism and the dummy round.
Abstract:
A formulation comprising, and process for preparing, improved oral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-null4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylnull-urea, a chemical entity with anti-inflammatory properties. Granulation of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-null4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylnull-urea within specified ranges provides improved dissolution of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-null4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylnull-urea and oral bioavailability, as well as content uniformity. Incorporation into the formulation of an aqueous soluble inclusion compound capable of forming a complex with 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-null4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylnull-urea, such as beta-cyclodextrin provides enhanced stability of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-null4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylnull-urea, in particular in highly ionic environments. Chipping and disintegration of tablets containing more than about 10% betacyclodextrin can be prevented by applying a polymeric coat to the surface of the tablet at a temperature below 40null C.
Abstract:
Apparatus and a concomitant method for electrostatically depositing select doses of medicament powder at select locations on a substrate. Specifically, the apparatus contains a charged particle emitter for generating charged particles that charge a predefined region of a substrate and a charge accumulation control circuit for computing the amount of charge accumulated upon the substrate and deactivating the emitter when a selected quantity of charge has accumulated. Additionally, a triboelectric charging apparatus charges the medicament powder and forms a charged medicament cloud proximate the charged region of the substrate. The medicament particles within the medicament cloud electrostatically adhere to the charged region. The quantity of charge accumulated on the substrate at the predefined region and the charge-to-mass ratio of the medicament powder in the cloud control the amount (dose) of medicament deposited and retained by the substrate. Consequently, this apparatus accurately controls both medicament dosage and deposition location. Furthermore, since the substrate can be of any dielectric material that retains an electrostatic charge, the apparatus can be used to deposit medicament on substrates that are presently used in oral medicament consumption, e.g., substrates that are used to fabricate suppositories, inhalants, tablets, capsules and the like.
Abstract:
Processes for utilizing various emulsion polymerization procedures for preparing aqueous nanocomposite dispersions are disclosed. The disclosed processes include both in-situ polymerizations in the presence of at least partially exfoliated unmodified clays as well as admixtures of polymer dispersions with at least partially exfoliated unmodified clay dispersions. The disclosed nanocomposite dispersions are useful for preparing a variety of materials, such as coatings, adhesives, caulks, sealants, plastics additives, and thermoplastic resins. Processes for preparing polymer clay nanocomposite powders and use of these powders as plastic resin and plastics additives are also disclosed.
Abstract:
A coating material includes sodium in a range of from 0.1% to 10%; magnesium in a range of from 0.01% to 1%; aluminum in a range of from 0.1% to 15%; potassium in a range of from 1% to 30%; silicon in a range of from 10% to 30%; and iron in a range of from 0.1% to 1%.
Abstract:
The invention relates to a complex coacervation process based on the use of type B gelatin as polycationic colloid, for the preparation of nullHalalnull certified flavor-containing microcapsules.
Abstract:
The invention concerns a method for coating solid particles with a thermofusible agent which consists in: fluidizing the solid particles in an ascending air movement in spiral rotation to obtain a homogeneous individualised distribution of the particles in the air fluidized bed, the temperature of the air fluidized bed being lower than the melting point of the thermofusible agent; spraying on the particles the melted thermofusible agent in the form of atomised droplets, said droplets being distributed in a spraying cone included in an air zone, whereof the temperature enables to maintain, throughout said spraying process, a temperature of the thermofusible agent substantially equal its melting point, the spraying being carried out in the same direction and tangentially to the movement followed by the solid particles; finally, after the coating process, cooling the resulting coated particles so as to solidify the thermofusible agent around the particles.
Abstract:
There is disclosed a frictionizing composition for imparting long-term anti-slip properties to the surface of a paper product comprising an aqueous sol of colloidal silica, glycerin, and at least one agent selected from the group consisting of N-methyl pyrrolidone, N,N-dimethyl acetoacetamide, urea, sorbitol, fructose and dextrose. The composition remains fluid, even after prolonged exposure to drying conditions, and thus is readily dispersible in water for easy cleanup of residue from apparatus and the work environment.
Abstract:
The invention relates to a substrate coating for the electrostatic deposition of dry powder medicaments for use in the manufacture of pharmaceutical dosage forms comprising micronized polyethylene glycol (PEG), with A molecular weight in the range of 1,000 to 20,000, and having a particle size of 1-100 nullm. The invention also relates to pharmaceutical compositions having such a substrate coating, and processes for manufacturing such pharmaceutical compositions. The invention also relates to the technology of reversing negative charge of medicaments so that they can be electrostatically deposited on a negatively charged substrate.
Abstract:
A method of enhancing oxidation of air contaminants on an ultra-low density, UV light accessible aerogel photocatalyst is provided. The method includes the steps of providing a photocatalytic reactor system broadly comprising a photocatalytic reactor cell, a UV light source, and a pump to force the contaminated air stream through the photocatalytic reactor cell. The photocatalytic reactor cell includes glass cell. A catalyst bed formed of a titanium dioxide aerogel is provided in the glass cell whereby a high fraction of the titanium dioxide aerogel is accessible to UV light and gas. The catalyst bed is exposed to UV light from the UV light source and a contaminated air stream is introduced into the photocatalytic reactor cell such that the air stream passes through the catalyst bed causing oxidation of the contaminants of the air stream.